The safety and tolerability of quetiapine (up to 75 mg/day) as monotherapy on essential tremor were investigated in an open-label study in 10 patients. Five men and 5 women, with a mean age of 66.3 years, affected by essential tremor participated in the trial. They were treated with increasing doses of quetiapine to 75 mg/day over a 6-week period. Side effects included a paradoxical psychiatric reaction in one and anger in another, and in both cases quetiapine was discontinued. In two other patients, somnolence led to dose reduction. There were no pre- versus post-treatment differences, but 3 out of 10 patients benefited (improvement >20%). Although the study was not powered to assess efficacy, quetiapine seems to be a safe drug for the treatment of essential tremor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00002826-200211000-00004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Essential tremor: tips and tricks.
Pract Neurol
March 2025
Neurology, 12 de Octubre University Hospital, Madrid, Comunidad de Madrid, Spain.
Tremors are a common reason for neurology consultations and can sometimes be a diagnostic challenge. One of the most common causes is essential tremor, which needs to be distinguished from other types of tremors, such as those found in Parkinson's disease, cerebellar disease or dystonic tremor. This categorisation is important as their treatment and prognosis differ.
View Article and Find Full Text PDFHigher Prevalence of Common Neurological Soft Signs in Essential Tremor With Midline Distribution: A Multicenter Cohort Study.
J Clin Neurol
March 2025
Department of Geriatric Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Background And Purpose: Essential tremor with a midline distribution (Mid-ET) may represent a distinct subtype of essential tremor (ET) that primarily affects midline structures, often indicating advanced disease stage and increased severity. Recent studies have highlighted the complexity of Mid-ET, but research on neurological soft signs (NSS) in Mid-ET remains insufficient.
Methods: The patients with ET included in this cross-sectional study were divided into two subgroups based on whether or not the ET had a midline distribution: Mid-ET and No-Mid-ET.
Ultrasound-Guided Botulinum Toxin Infiltrations in Essential Tremor Patients: A 36-week Follow Up.
Tremor Other Hyperkinet Mov (N Y)
March 2025
Department of Neurology, Consorci Sanitari de Terrassa, Barcelona, Spain.
Background: Essential tremor (ET) presents therapeutic challenges as oral therapies, are often partially effective and carry adverse effects. Deep Brain Stimulation and High-intensity Focused Ultrasound targeting the ventral intermediate thalamic nucleus show efficacy in managing ET; however, their cost and invasiveness deter some patients. Botulinum toxin infiltrations for ET in the upper limbs have been limited by adverse effects.
View Article and Find Full Text PDFSafety of Focused Ultrasound Ablation in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials.
J Clin Neurosci
March 2025
Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Introduction: Magnetic resonance-guided focused ultrasound (MRgFUS) is well-established for the treatment of essential tremor and is emerging as a promising non-incisional treatment for Parkinson's disease (PD). However, its safety in this context is not well established.
Methods: We performed a systematic review and meta-analysis to evaluate the incidence of adverse events among patients with medication-refractory PD treated with MRgFUS.
Cerebellar transcranial magnetic stimulation in essential tremor: a systematic review and meta-analysis of safety and efficacy.
Acta Neurol Belg
March 2025
Department of Neurology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Background: Essential tremor (ET) is a common neurological disorder that significantly impacts daily activities. This meta-analysis aims to evaluate the safety and efficacy of cerebellar repetitive Transcranial Magnetic Stimulation (rTMS) and cerebellar Theta Burst Stimulation (TBS) in treating ET.
Methods: We searched through June 14, 2024, four databases (Scopus, PubMed, Web of Science, and Cochrane CENTRAL) to identify clinical trials investigating cerebellar rTMS or TBS in ET patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!